{"id":"topiramate-standard","safety":{"commonSideEffects":[{"rate":"10-15%","effect":"Cognitive impairment / memory problems"},{"rate":"15-20%","effect":"Paresthesia"},{"rate":"5-10%","effect":"Weight loss"},{"rate":"10-15%","effect":"Fatigue"},{"rate":"10-15%","effect":"Dizziness"},{"rate":"<1%","effect":"Acute myopia / angle-closure glaucoma"}]},"_chembl":{"chemblId":"CHEMBL220492","moleculeType":"Small molecule","molecularWeight":"339.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topiramate is a sulfamate-substituted monosaccharide that acts through multiple mechanisms: it blocks voltage-gated sodium channels, potentiates GABA-A receptor activity, and inhibits carbonic anhydrase. These combined effects reduce neuronal firing and synaptic transmission, making it effective for seizure suppression and migraine prevention.","oneSentence":"Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:19.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy / seizure disorders"},{"name":"Migraine prophylaxis"},{"name":"Bipolar disorder (off-label)"}]},"trialDetails":[{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT07027969","phase":"PHASE4","title":"Metabolic Surgery for Atrial Fibrillation Elimination","status":"NOT_YET_RECRUITING","sponsor":"Ali Aminian","startDate":"2026-02-01","conditions":"Atrial Fibrillation, Obesity and Obesity-related Medical Conditions","enrollment":100},{"nctId":"NCT06303778","phase":"NA","title":"Combining a Smartphone App With Medications to Manage Heavy Drinking","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-11-01","conditions":"Alcohol Use Disorder (AUD)","enrollment":330},{"nctId":"NCT05756764","phase":"","title":"Anti-obesity Pharmacotherapy and Inflammation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2023-06-01","conditions":"Obesity","enrollment":30},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT04572217","phase":"PHASE2","title":"Medications After Adolescent Bariatric Surgery","status":"WITHDRAWN","sponsor":"Janey Pratt","startDate":"2022-06-01","conditions":"Pediatric Obesity","enrollment":""},{"nctId":"NCT04095104","phase":"PHASE2","title":"Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-15","conditions":"Obesity, Morbid, Bariatric Surgery, Adolescent","enrollment":13},{"nctId":"NCT05812183","phase":"PHASE4","title":"Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2023-07-09","conditions":"Dyspnea, Quality of Life","enrollment":""},{"nctId":"NCT03671681","phase":"PHASE4","title":"Mindfulness Therapy for Chronic Migraine","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2018-11-05","conditions":"Chronic Migraine, Medication Overuse Headache","enrollment":177},{"nctId":"NCT05263674","phase":"PHASE3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Non-Convulsive Status Epilepticus","enrollment":140},{"nctId":"NCT04531176","phase":"PHASE4","title":"EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-09-01","conditions":"Type 2 Diabetes, Obesity","enrollment":74},{"nctId":"NCT01765218","phase":"PHASE1, PHASE2","title":"Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy","status":"TERMINATED","sponsor":"Kristin R Hoffman","startDate":"2013-02","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":34},{"nctId":"NCT05403229","phase":"PHASE2","title":"The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-10-17","conditions":"Sudden Deafness, Sudden Sensorineural Hearing Loss","enrollment":140},{"nctId":"NCT00777218","phase":"NA","title":"Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine","status":"WITHDRAWN","sponsor":"University of South Alabama","startDate":"2007-08","conditions":"Migraine","enrollment":""},{"nctId":"NCT02993861","phase":"","title":"Pharmacokinetics of Anti-epileptic Drugs in Obese Children","status":"COMPLETED","sponsor":"Christoph P Hornik, MD MPH","startDate":"2016-12-09","conditions":"Epilepsy, Obese","enrollment":106},{"nctId":"NCT02643719","phase":"NA","title":"Migraine Treatment in ED","status":"WITHDRAWN","sponsor":"NYU Langone Health","startDate":"2015-12","conditions":"Migraine","enrollment":""},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35},{"nctId":"NCT01060111","phase":"PHASE4","title":"An Efficacy and Tolerability Study of Topiramate in Participants With Migraine","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2006-07","conditions":"Migraine","enrollment":250},{"nctId":"NCT00772031","phase":"PHASE3","title":"NINDS CRC Chronic Migraine Treatment Trial","status":"COMPLETED","sponsor":"Anne Lindblad","startDate":"2008-10","conditions":"Chronic Migraine","enrollment":191},{"nctId":"NCT00236717","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"1997-09","conditions":"Epilepsy, Seizures","enrollment":865}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":313,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Topiramate Standard","genericName":"Topiramate Standard","companyName":"Janssen Korea, Ltd., Korea","companyId":"janssen-korea-ltd-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Topiramate blocks sodium channels and enhances GABA-mediated inhibition in the central nervous system to reduce neuronal excitability. Used for Epilepsy / seizure disorders, Migraine prophylaxis, Bipolar disorder (off-label).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}